Alzheimer's patch Adlarity forecast to exceed $200 million in US sales by 2030

Earlier this month, CNS specialist Corium won US Food and Drug Administration (FDA) approval for Adlarity (donepezil hydrochloride) to treat patients with mild, moderate, or severe dementia of Alzheimer’s disease (AD).

But data and analytics company GlobalData has warned that, as Adlarity is the fourth cholinesterase inhibitor product to launch in the US market, it enters a fiercely competitive space for the symptomatic treatment of AD.

GlobalData forecasts that cholinesterase inhibitors are forecast to contribute a combined $895.9 million to the US AD market by 2030. These include Adlarity, which is a single patch that is placed by the patient or caregiver on the patient’s back, thigh, or buttocks. Its once-weekly application will set it apart from other cholinesterase products with more frequent daily oral or transdermal dosing.